Get the Stockscreener App
1.695
2.31%
-0.04
After Hours:
1.63
-0.065
-3.83%
Intercure Ltd stock is traded at $1.695, with a volume of 15,791.
It is down -2.31% in the last 24 hours and down -9.36% over the past month.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. The products are distributed to hospitals, pharmacies, research, and government organizations. The company has two segments namely: Cannabis segment and Biomed segment, out of which it derives maximum revenue from Cannabis segment.
See More
Previous Close:
$1.735
Open:
$1.73
24h Volume:
15,791
Relative Volume:
0.61
Market Cap:
$77.57M
Revenue:
$118.18M
Net Income/Loss:
$5.99M
P/E Ratio:
12.85
EPS:
0.1319
Net Cash Flow:
$-12.91M
1W Performance:
-2.59%
1M Performance:
-9.36%
6M Performance:
-45.67%
1Y Performance:
+55.50%
1-Day Range:
$1.68
$1.73
1-Week Range:
$1.68
$1.79
52-Week Range:
$1.01
$3.72
Intercure Ltd Stock (INCR) Company Profile
Intercure Ltd Stock (INCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-18-22 | Upgrade | Canaccord Genuity | Speculative Buy → Buy |
Intercure Ltd Stock (INCR) Latest News
InterCure Ltd. (NASDAQ:INCR) Sees Significant Drop in Short Interest - MarketBeat
InterCure Ltd. (NASDAQ:INCR) Sees Large Decline in Short Interest - MarketBeat
Synbiotic's CAGR Forecast at 80%, ECS Botanics to Expand Footprint in Germany, & More from Intercure - Business of Cannabis -
Are Investors Missing The Forest? 35% Stock Drop Masks The International Potential Of This Weed Company - Benzinga
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - Market Exclusive
InterCure Ltd. (NASDAQ:INCR) Sees Significant Increase in Short Interest - MarketBeat
Top Seller Of Pharmaceutical Cannabis Outside US Grew By Double-Digits, Focuses On Germany - Benzinga
InterCure nears break even in first half of 2024, despite ongoing Israel-Hamas war - Green Market Report
InterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 million - GlobeNewswire
InterCure Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024 - Marketscreener.com
InterCure partners with Cookies to launch cannabis pharmacies in Germany By Investing.com - Investing.com Australia
InterCure partners with Cookies to launch cannabis pharmacies in Germany - Investing.com
InterCure Announces Expansion of its Strategic partnership with Cookies to Germany - Business Wire
InterCure (NASDAQ:INCR) Stock Price Up 0.5% - MarketBeat
Tidal Investments LLC Invests $883,000 in InterCure Ltd. (NASDAQ:INCR) - American Banking and Market News
Cannabis News: Majority of Americans Want Rescheduling or Legalization; European Market Growth Could be Game-Changer; Spotlight on InterCure - Market Research Record
Support for Regulatory Changes Surrounding Cannabis Remains Strong in the US, Companies Like InterCure Could Also Benefit From Growth in Europe - Markets Herald
Mirae Asset Global Investments Co. Ltd. Sells 467,995 Shares of InterCure Ltd. (NASDAQ:INCR) - Defense World
InterCure Ltd. (NASDAQ:INCR) Stake Cut by Mirae Asset Global Investments Co. Ltd. - MarketBeat
InterCure (NASDAQ:INCR) Shares Up 1% - MarketBeat
InterCure (NASDAQ:INCR) Trading 1% Higher - Defense World
InterCure: A Cannabis Industry Leader Still Flying Under The Radar (NASDAQ:INCR) - Seeking Alpha
InterCure (NASDAQ:INCR) Trading Down 1.2% - MarketBeat
The market capitalization of InterCure chaired by Ehud Barak is 1.000 billion shekels - Aurora Israel
IM Cannabis Merger Scrapped, Cel AI Gets a New CEO, & More from Intercure - Business of Cannabis -
Asset-Light Expansion Into $8B German Market Adds Potential To This Cannabis Stock On NASDAQ - Markets Insider
The Daily Hit: May 23, 2024 - Green Market Report
InterCure stock initiated with Overweight rating by Zuanic & Associates By Investing.com - Investing.com
Analyst: Israel's InterCure paving path to big gains - Green Market Report
Leading analyst gives InterCure overweight rating, noting 5x returns potential - FXStreet
Analyst: Israel’s InterCure paving path to big gains - Green Market Report
Intercure Ltd. Files SEC Report, Ensures TransparencyTipRanks.com - TipRanks
InterCure to Participate in Canaccord Genuity's 8th Annual Global Cannabis Conference - Business Wire
InterCure to Participate in Canaccord Genuity’s 8th Annual Global Cannabis Conference - Yahoo Finance
InterCure (NASDAQ:INCR) Trading Down 4.1% - MarketBeat
InterCure (NASDAQ:INCR) Stock Price Down 4.1% - Defense World
Medical Cannabis Company Better Is Suing InterCure For $35M - MSN
InterCure Reports Strong FY2023: Performance Paves the Way for Global Expansion - Benzinga
InterCure Announces FY2023 Results: Revenue of NIS 356 million and Adjusted EBITDA of NIS 61 million - Business Wire
InterCure: Bargain Israel Cannabis Play (NASDAQ:INCR) - Seeking Alpha
Here's What You Missed in Cannabis, Psychedelics This WeekTipRanks.com - TipRanks
InterCure Announces Preliminary Estimated 2023 Revenue of NIS 351 million and EBITDA of over NIS 50 million - Business Wire
symbol__ Stock Quote Price and Forecast - CNN
InterCure Congratulates Germany on Cannabis Reform, Expanding its Global Footprint - Business Wire
InterCure Provides Update Regarding Nir Oz Facility in Israel - Cannabis Business Times
InterCure Provides an Update Regarding Nir Oz Facility - GlobeNewswire
InterCure Signs Definitive Agreement to Acquire Leon Cannabis Pharmacy Chain - Yahoo Finance
Israeli Cannabis Firms Navigate Challenges Amid Hamas Conflict, Cellular Goods Signs New Joint Venture, & More from SEED Innovations - Business of Cannabis -
InterCure Provides an Update Regarding the Security Situation in Israel - Financial Post
Israeli Cannabis Adjusts to War - Green Market Report
InterCure Announces Record Revenues First Half of 2023 with over 14% growth YOY - GlobeNewswire
Intercure Ltd Stock (INCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.88%
0.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):